ImmunoGen stops Phase II study of lung-cancer treatment

ImmunoGen (IMGN) has halted a Phase II trial of its IMGN901 drug in patients with small-cell lung cancer, due to too many infections and infection-related deaths.

The Data Monitoring Committee of the study concluded that the use of IMGN901 was unlikely to demonstrate a sufficient improvement in progression-free survival. (PR)

However, ImmunoGen has initiated Phase I testing of IMGN289, a potential treatment for lung, head and neck tumors. (PR)

Shares are -9.4%.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs